Axon Neuroscience’s Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant
Axon Neuroscience’s active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to